Skinvisible, Inc. SKVI Archives - Page 3 of 4

FridayDec 15, 2017 1:58 pm

QualityStocksNewsBreaks – Skinvisible, Inc. (SKVI) Advances Invisicare Delivery System

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) is targeting the pharmaceutical industry with its proprietary drug delivery system, Invisicare. Invisicare improves the delivery of ingredients to and through the skin. An article discussing this reads: “Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products,…

WednesdayDec 13, 2017 3:21 pm

New Exclusive Licensing Agreement with Cannabiniers, Conducted via Lighthouse Strategies with Skinvisible (SKVI) Subsidiary

Cannabis industry pioneer Cannabiniers will distribute treatments utilizing Invisicare®, a patented polymer delivery system Agreement marks continued growth for Skinvisible’s subsidiary Ovation Science Inc. Patented delivery technology enables improved controlled release of topically applied products Research and development company Skinvisible, Inc. (OTCQB: SKVI) has announced that its subsidiary Ovation Science Inc. has forged a definitive license agreement with Lighthouse Strategies LLC, through its multifaceted cannabis technology and brand management company Cannabiniers, to utilize the Company’s products formulated with its patented pharmaceutical polymer in serving the U.S. cannabis market (http://dtn.fm/1eB6Q). The Lighthouse agreement grants the company exclusive use of Ovation’s new…

FridayDec 08, 2017 2:24 pm

QualityStocksNewsBreaks – Skinvisible, Inc. (SKVI) Poised for Growth More than Skin Deep

Skinvisible (OTCQB: SKVI) is poised for growth in the booming global topical drug delivery market. A recent article highlights the company’s positioning, stating, “The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good…

TuesdayDec 05, 2017 1:08 pm

Skinvisible, Inc. (SKVI) Maximizes Product Development Opportunities with Global Goals

Targeting unmet medical needs with proprietary topical formulations License-based business model translates to worldwide opportunities Patented Invisicare™ technology offers enhanced drug delivery system Global skincare market projected to reach $135 billion by 2021 Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), continues to add significant value to its core business model with several key movements involving a proposed merger, new licensing agreements and formation of a specialized subsidiary. The Company’s November 27 announcement that it has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd., pending customary closing conditions, melds industry veterans committed to…

MondayDec 04, 2017 12:00 pm

Skinvisible, Inc.’s (SKVI) Topical Drug Delivery System Set to Enjoy New Licensing Opportunities

Proven patented polymer drug delivery technology Global topical drug delivery market set for CAGR of 9.2% over next 7 years Strategy to derive revenues from royalties and other licensing fees Skinvisible, Inc. (OTCQB: SKVI) is set for a business renaissance in the coming years. The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow…

MondayNov 27, 2017 10:52 am

QualityStocksNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Enters Non-Binding Term Sheet for Proposed Merger with Quoin Pharmaceuticals

Skinvisible Pharmaceuticals (OTCQB: SKVI) has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd. per the company’s announcement this morning. The completion of the proposed merger is subject to the negotiation of a definitive agreement and other customary closing conditions including tax, accounting, legal, and regulatory conditions. The new company would continue trading on the OTCQB market under the name Quoin Pharmaceuticals Inc. and is expected to have a robust product portfolio addressing major unmet medical needs. Post-merger, the new company will be 72.5% owned by Quoin shareholders and Skinvisible shareholders will own 27.5%, prior…

TuesdayNov 21, 2017 8:30 am

Skinvisible, Inc. (SKVI) Subsidiary Inks License Agreement for US Distribution of Topical Cannabis Products

Announces formation of new Canadian subsidiary Ovation Science Inc. Agreement forged with Lighthouse Strategies, LLC, regarding exclusive use of patented topical and transdermal formulations in select U.S. markets Licensing agreement recently made with Canopy Growth Corp. for exclusive rights in Canada Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) announced on November 16 that it has formed a new subsidiary, Ovation Science Inc., and that Ovation has inked a definitive license agreement with Lighthouse Strategies, LLC (http://dtn.fm/SLyx4). The agreement, made through Ovation, stipulates that Lighthouse will have exclusive use of the company’s patented topical and transdermal formulations for select…

MondayNov 20, 2017 3:49 pm

QualityStocksNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Could Have the Solution to the Flu Epidemic

Skinvisible Pharmaceuticals (OTCQB: SKVI) is a topical and transdermal product development company with a proprietary drug delivery system, Invisicare, that improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically, CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). The key to Skinvisible's patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Applications of this novel technology are discussed in a recent article that says in part, “H7N9 (a type of avian influenza virus) could…

ThursdayNov 16, 2017 1:12 pm

QualityStocksNewsBreaks – Skinvisible (SKVI) Inks Licensing Agreement for Distribution of Topical Cannabis Products in Select U.S. Markets

Pharmaceutical solutions researcher Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) this morning said its Ovation Science subsidiary has reached a licensing agreement with Cannabiniers, a subsidiary of Lighthouse Strategies, LLC, to distribute Skinvisible’s patented Invisicare transdermal drug-delivery technology to select markets in the United States where medical cannabis products have been legalized. "We are excited to have Cannabiniers as a partner in the U.S. cannabis market. They are branding experts and have the vision and infrastructure to take Ovation's cannabis products across the United States," Skinvisible President Terry Howlett stated in the press release. "Leveraging Cannabiniers branding strategies, we have the ability to…

ThursdayNov 09, 2017 4:12 pm

Could Skinvisible (SKVI) Have the Answer to a Potential New Global Flu Pandemic?

Skinvisible Pharmaceuticals, Inc. is making confident steps toward the large-scale distribution of its hand sanitizer in China Clinical studies show that frequent hand sanitization is the only effective non-pharmaceutical measure for influenza prevention Worries about the spread of avian influenza and its high mortality rate have triggered the introduction of more rigorous prophylactic measures and market growth H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://dtn.fm/Nby8B). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI)…

Site Search

Company Search

Tag: Skinvisible, Inc. SKVI